Zai Lab (ZLAB) AI Stock Analysis

Compare

644 Followers

ZLAB Dividends

Top Page

Zai Lab

(NASDAQ:ZLAB)

55Neutral

Zai Lab shows strong revenue growth and a positive outlook from its earnings call, highlighting successful product launches and a solid cash position. However, significant risks remain due to its ongoing unprofitability, negative cash flows, and the need for external financing. Technical indicators are mixed, with some positive momentum but potential short-term bearish signals. Valuation concerns persist due to the negative P/E ratio, reflecting the company's current lack of profitability.

Positive Factors

Market Capture

Zai Lab's niraparib captured 43.9% of the market in terms of sales within the PARP inhibitor market in China.

Revenue Growth

Zai Lab registered total revenue of US$399.0mn, which is in line with the forecast and shows significant growth.

Sales Performance

VYVGART showed an impressive sales ramp-up, significantly contributing to the company's overall revenue growth.

Negative Factors

Competitor Impact

The entry of more competitors is affecting Zai Lab's core product market.

Geopolitical Concerns

Rising US/China trade tensions and national security concerns are impacting investor sentiment towards ZLAB.

Sales Decline

There is a noticeable decline in the month-over-month drug sales for Zai Lab's products.

Zai Lab (ZLAB) vs. S&P 500 (SPY)

Market Cap

$3.58B

Dividend YieldN/A

Average Volume (3M)1.44M

Price to Earnings (P/E)―

Beta (1Y)0.96

Revenue Growth49.59%

EPS Growth24.92%

CountryUS

Employees1,869

SectorHealthcare

Sector Strength57

IndustryBiotechnology

Share Statistics

EPS (TTM)-2.60

Shares Outstanding110,328,380

10 Day Avg. Volume999,128

30 Day Avg. Volume1,437,357

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

Price to Cash Flow (P/CF)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.50

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit7.09

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$53.22

Price Target Upside70.69% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Zai Lab Business Overview & Revenue Model

Company DescriptionZai Lab Limited (NASDAQ: ZLAB) is a leading, innovative biopharmaceutical company headquartered in Shanghai, China. The company is dedicated to the development and commercialization of innovative therapies that address medical needs in oncology, autoimmune, and infectious diseases. Zai Lab focuses on bringing transformative medicines to patients in China and around the world, leveraging its strong R&D capabilities and strategic partnerships with global pharmaceutical companies.

How the Company Makes MoneyZai Lab makes money through the development, commercialization, and sales of its pharmaceutical products. The company's revenue model includes income generated from the sale of drugs and therapies, primarily in the areas of oncology, autoimmune disorders, and infectious diseases. Additionally, Zai Lab engages in strategic collaborations and partnerships with global pharmaceutical companies, which provide upfront payments, milestone payments, and royalties. These partnerships are crucial for accessing advanced technologies and expanding the company's product pipeline, thereby contributing significantly to its revenue streams.

Zai Lab Financial Statement Overview

Summary

Zai Lab exhibits strong revenue growth but faces profitability and cash flow challenges. The balance sheet is stable with low leverage, a positive in the capital-intensive biotech industry. However, ongoing losses and negative cash flows raise concerns about achieving sustainable profitability. Continued reliance on external financing could be risky if positive cash flows and net income aren't achieved.

Income Statement

Negative

Zai Lab has shown consistent revenue growth over the years, with a significant increase from $12.98 million in 2019 to $398.99 million in 2024, reflecting a strong upward trajectory. However, the company is still facing considerable losses, with negative EBIT and net income margins, indicating ongoing profitability challenges. The net profit margin remains in negative territory, at -64.45% for 2024, suggesting that the company is still struggling to turn its revenue growth into profitability.

Balance Sheet

Neutral

The balance sheet shows a stable equity position with stockholders' equity of $840.90 million in 2024. The debt-to-equity ratio is low at 0.18, indicating low leverage and financial stability. However, the return on equity is negative due to the company's ongoing losses, which is a concern for long-term profitability. The equity ratio remains strong at 70.93%, reflecting a solid asset base funded by equity.

Cash Flow

Neutral

The company has demonstrated some improvements in free cash flow, but it remains negative at -$220.53 million in 2024. Operating cash flow has improved slightly but is still negative, showing that the company is not yet generating positive cash from its operations. The cash flow from financing activities is positive, indicating that the company has been able to raise funds, but reliance on external funding is significant. The free cash flow to net income ratio is unfavorable due to the negative net income.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
398.99M	266.72M	215.04M	144.31M	48.96M
	Gross Profit
251.13M	170.90M	141.02M	92.07M	32.22M
	EBIT
-282.12M	-366.57M	-404.36M	-700.06M	-301.80M
	EBITDA
-242.99M	-365.11M	-384.66M	-689.46M	-262.96M
	Net Income Common Stockholders
-257.10M	-334.62M	-481.99M	-692.44M	-298.16M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
779.67M	806.45M	1.01B	1.41B	1.19B
	Total Assets
1.19B	1.04B	1.22B	1.61B	1.30B
	Total Debt
153.47M	15.15M	20.39M	15.54M	18.60M
	Net Debt
-296.20M	-775.00M	-988.08M	-948.56M	-423.52M
	Total Liabilities
344.86M	240.18M	174.54M	230.00M	128.29M
	Stockholders Equity
840.90M	796.12M	1.05B	1.38B	1.17B
Cash Flow		Free Cash Flow
-276.39M	-206.67M	-392.63M	-568.18M	-226.72M
	Operating Cash Flow
-214.87M	-198.18M	-367.64M	-549.23M	-216.06M
	Investing Cash Flow
-375.19M	-10.78M	420.02M	249.96M	-554.83M
	Financing Cash Flow
349.89M	-6.43M	-1.73M	820.20M	1.13B

Zai Lab Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price31.18

Price Trends

50DMA

33.56

Negative

100DMA

30.21

Positive

200DMA

26.79

Positive

Market Momentum

MACD

-0.34

Negative

RSI

47.45

Neutral

STOCH

33.98

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZLAB, the sentiment is Neutral. The current price of 31.18 is above the 20-day moving average (MA) of 30.41, below the 50-day MA of 33.56, and above the 200-day MA of 26.79, indicating a neutral trend. The MACD of -0.34 indicates Negative momentum. The RSI at 47.45 is Neutral, neither overbought nor oversold. The STOCH value of 33.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ZLAB.

Zai Lab Risk Analysis

Zai Lab disclosed 100 risk factors in its most recent earnings report. Zai Lab reported the most risks in the “Finance & Corporate” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Zai Lab Peers Comparison

Overall Rating

UnderperformOutperform

Sector (52)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OPCH	76 Outperform	$5.40B	26.32	15.38%	―	16.98%	-17.76%
SHC	68 Neutral	$3.51B	142.96	5.88%	―	2.78%	-54.72%
ELAN	65 Neutral	$4.84B	14.37	5.49%	―	0.50%	―
ZLAB	55 Neutral	$3.58B	―	-31.41%	―	49.59%	24.92%
Sector *	52 Neutral	$5.35B	3.96	-42.60%	2.86%	17.58%	1.27%
RNA	46 Neutral	$3.87B	―	-33.47%	―	13.99%	0.17%
PTCT	42 Neutral	$3.94B	―	33.08%	―	-13.97%	43.51%

* Healthcare Sector Average

Performance Comparison

ZLAB

Zai Lab

31.18

14.27

84.39%

OPCH

Option Care Health

32.95

2.93

9.76%

PTCT

PTC Therapeutics

49.95

16.99

51.55%

ELAN

Elanco Animal Health

9.75

-3.51

-26.47%

RNA

Avidity Biosciences

32.20

5.87

22.29%

SHC

Sotera Health

12.38

1.09

9.65%

Zai Lab Earnings Call Summary

Earnings Call Date:Feb 27, 2025

(Q4-2024)

% Change Since: -11.09%|

Next Earnings Date:May 08, 2025

Earnings Call Sentiment Positive

The earnings call reflects a positive sentiment with strong revenue growth, successful product launches, and pipeline advancements. Despite some challenges, such as limited immediate impact from certain product launches and competitive pressures, the company is on track towards profitability and maintains a strong cash position.

Q4-2024 Updates

Positive Updates

Record Revenue Growth

Total revenue for 2024 grew 50% year-on-year, with a 66% growth in the fourth quarter. Full-year revenue was $399 million.

Successful Launches and Product Performance

VYVGART generated $93.6 million in sales in its first year, with fourth quarter sales of $30 million. New products like VYVGART Hytrulo, AUGTYRO, and XACDURO were launched successfully.

Pipeline Advancements

Significant progress in the pipeline, including positive data readouts for KarXT, Tumor Treating Fields, and TIVDAK. Regulatory submissions and approvals are on track for multiple products.

Cost Efficiency and Profitability Outlook

Loss from operations improved by 45% in Q4 and 23% for the full year. The company is on track to reach profitability by Q4 2025.

Strong Cash Position

The company maintains a robust cash position of $879.7 million to support future growth.

Negative Updates

Limited Immediate Impact of CIDP and Hytrulo Launches

VYVGART Hytrulo and CIDP are not listed on the NRDL for 2025, leading to limited market impact due to reliance on supplemental insurance or cash payments.

Competitive Landscape for DLL3

DLL3 faces competition from other advanced therapies, such as tarlatamab, which may impact market dynamics.

Company Guidance

During the call, Zai Lab provided detailed guidance on its performance and expectations. For 2025, the company anticipates total revenues to be between $560 million and $590 million, reflecting strong growth from products such as VYVGART, ZEJULA, and NUZYRA. The company reported a 66% increase in fourth-quarter revenue to $109.1 million and a 50% rise for the full year, totaling $399 million. VYVGART, which generated $93.6 million in 2024, is expected to drive significant growth, with new formulations and approvals anticipated to enhance its market penetration. Zai Lab aims to achieve profitability by the fourth quarter of 2025, driven by operational efficiencies that have already resulted in a 45% reduction in fourth-quarter operational loss and a 23% decrease for the full year. The company maintains a robust cash position of $879.7 million to support its growth strategy, including advancing its pipeline and launching new products.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.